CORRESPONDENCE
when the infant demonstrated adequate tone and wakefulness. Upon arrival in the PACU, the infant's temperature was 36.4~ respiratory rate 30-35 per minute, heart rate 180-190 bpm, and the SpO2 was 100% breathing 0.4 FIO2. The infant's nurse, noting that the/v solution was not infusing, injected saline through an injection port. 'Approximately ten minutes later, the patient's cry began to weaken and take on a whispering quality, at which time a house officer was summoned. Within one minute the infant became apnoeic and cyanosed, with a heart rate of 70 bpm. Resuscitation commenced immediately with 100% oxygen administered by bag and mask, followed by tracheal intubation. The infant made no effort to breath spontaneously and a nerve stimulator revealed no response to supramaximal tetanic stimulation. Twelve minutes later one twitch on TOF testing returned and /v neosfigmine 0.4 mg was given. Within five minutes the patient regained spontaneous ventilation, and good physical strength. Nerve stimulation revealed four strong twitches and sustained tetanus at 50 Hz. The trachea was extubated and the remainder of her postoperative course was uneventful.
Residual neuromuscular blockade is a concern in the PACU, ~ but recurarization after seemingly adequate reversal is rare. A retrospective review of 16,700 children reported no PACU complications related to residual paralysis, 2 nor did a prospective study involving I0,000 children. 3 The weak cry which progressed to apnoea and cyanosis, and absence of twitches on train-of-four monitoring, both of which responded to an additional dose of reversal agent, were clear manifestations of recurrent neuromuscular blockade. Upon careful review of the foregoing events we were unable to fmd evidence of insufficient reversal dose, undetected subcutaneous infiltration, or administration of other drugs with potential neuromuscular blocking properties (e.g., antibiotics). However, we were unable to exclude unintentional administration of residual mivacurium in the/v tubing when saline was flushed through the injection port. To our knowledge, this is the first published report of this postoperative complication in a paediatric patient. Although a technical source of this complication is most likely, an unknown cause related to the use of mivacurium in infants cannot be excluded and thus it is prudent that anaesthetists carefully monitor infants when using and reversing mivacurium, as sufficient data has not yet accumulated in this population. 
Vecuronium neuromuscular block in patients with malignant obstructive jaundice
To the Editor: Vecuronium has a shorter duration of action than equipotent doses of pancuronium. ~ The plasma clearance of vecuronium is decreased markedly in patients with hepatic cirrhosis, 2 and in patients with cholestasis. 3 The present report demonstrates a prolonged neuromuscular block when vecuronium was used in two patients having malignant obstructive jaundice.
The first patient was a 53-yr-old man, with an adenocarcinoma of the hepatic duct. The second was a 66-yr-old man with cancer of the head of the pancreas. Both were scheduled for cholecystectomy and hepaticojejunostomy. Anaesthesia was induced with thiopentone 5 rag. kg-I followed by vecuronium 0.1 rag. kg-I. When complete neuromuscular block was achieved, the trachea was intubated and anaesthesia was maintained with nitrous oxide:oxygen (3:1), supplemented with fentanyl 2 gtg. kg-I and intermittent doses of vecuronium 0.015 mg. kg-'. Neuromuscular transmission was monitored by trainof-four electromyography (Date.x) of the adductor pollicis. In the two patients, vecuronium 0.1 mg. kg -I resulted in complete neuromuscular block followed by slow recovery. A T4/TI twitch ratio of 0.I was observed only after 45 rain. Subsequent doses of vecuronium 0.015 mg. kg-' were required every 25-30 rain to maintain T4/T, ratio of 0;1.
Vecuronium, being monoquaternary, may be relatively lipophilic and this may favour its rapid entry into hepatocytes. 4 More than 40% of vecuronium injected /v is eliminated, mostly unchanged, in the bile. 5,6 Hepatic uptake could be the limiting factor for elimination of ve-curonium by the liver, since biliary secretion occurs at a slow rate. After the drug has been taken up by the liver, it is partially metabolized, stored, and secondarily released slowly in the bile or in the hepatic venous blood. Therefore, in patients with biliary obstruction, hepatic uptake may still continue despite the absence of biliary secretion. 3 However, an increase in the plasma concentration of bile salts has been shown to inhibit the hepatic uptake of vecuronium.7 Also, the vecuronium taken up by the liver may be redistributed back into the circulation.
The present report suggests prolongation of neuromuscular block following vecuronium in two patients with malignant severe obstructive jaundice. The prolonged block may be attributed to decreased uptake of vecuronium by the liver and/or delayed elimination in the bile. A smaller dose of vecuronium may be required to maintain neuromuscular block in such patients, and continuous monitoring of the level of neuromuscular blocks is important.
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